Most Read News

According to reports, the business is also planning its participation in the auction of all mineral blocks that will take place in India.

Mahindra & Mahindra plans to establish a robust presence in the commercial vehicle segment exceeding 3.5 tonnes.

UTI Multi Cap Fund offers higher risk-adjusted returns through a systematic exposure to mid-caps and small caps

The company's top line, revenue from operations, declined 2.7% YoY at ₹778.8 crore in Q4 FY25, from ₹800.2 crore during the corresponding quarter of FY24.

EBITDA margin for the quarter stood at 15.7%, slightly lower than the 16.5% margin recorded in the corresponding period of the previous fiscal year.

The company also informed that the board has approved raising ₹25,000 Crore via bonds in one or more tranches.

In Q4FY25, net interest income (NII) came down 2% YoY at ₹1,563 crore, compared to ₹1,600 crore during the same period last year.

The company's net profit stood at ₹434.7 crore in Q4FY25, significantly higher compared to ₹140.3 crore recorded in the same quarter of the previous fiscal year.

The EBITDA of the company declined sharply to ₹21 crore, much lower than the ₹306.42 crore it clocked in the March quarter of the last financial year.

Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.